GENOSURE ARCHIVE°

HIV-1 NEXT GENERATION DNA SEQUENCING ASSAY FOR SUPPRESSION MANAGEMENT

Resistance Information In Suppressed Patients

GenoSure Archive[®] is designed to provide HIV-1 antiretroviral (ARV) drug resistance data when a patient's viral load is suppressed or too low for standard resistance testing. The assay interrogates the viral archive using next-generation sequencing (NGS) to provide a list of the archived mutations and assigns susceptibility calls of *sensitive, resistant,* or *resistance possible* based on those mutations.

GenoSure Archive Facilitates Regimen Changes

Advances in ARV drug therapy have resulted in many patients achieving and maintaining full viral suppression. Increasingly common today is the need for "fine tuning" regimens while the patient's virus remains suppressed. Reasons for this include:


- Side effects
- Adverse events
- Regimen simplification
- Drug-drug interactions
- Concern for long-term toxicities
- Regimen intolerance

GenoSure Archive provides valuable information for nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase Inhibitors (NNRTIs), integrase inhibitors (INIs) and protease Inhibitors (PIs) when considering regimen switches in virologically suppressed patients:

- Information regarding archived drug resistance mutations and the effectiveness of accompanying ARV drugs is critical when considering regimen switches.¹
- In a 2013 study, patients fully suppressed on an ARV regimen consisting of a boosted protease inhibitor and two NRTIs, were switched to a new single tablet regimen based on historical, pre-suppression, viral RNA resistance data. The study demonstrated favorable concordance between Monogram's HIV-1 DNA resistance profiles and historical plasma viral resistance profiles among enrolled patients.²

Suppression Management

GenoSure Archive is the newest suppression management offering by Monogram Biosciences. In 2010, Monogram launched Trofile® DNA to assess HIV-1 tropism when considering a CCR5 antagonist in suppressed patients. Together, GenoSure Archive and Trofile DNA provide a comprehensive assessment of five ARV drug classes to facilitate regimen simplification or switches in the setting of virologic suppression.



The Viral Archive - A Second Source of Resistance Information

Differences can exist between the viral population circulating in the plasma and the proviral DNA archived in infected cells.

- Viral loads and standard resistance assays analyze viral RNA in plasma. GenoSure Archive analyzes archived HIV-1 proviral DNA embedded in host cells during virus replication.
- In the context of emerging treatment failure, ARV drug resistant HIV-1 variants are identified earlier in the plasma compartment relative to infected cells³, but resistant variants may persist longer in the infected cells⁴, especially in the absence of on-going drug pressure.
- **GenoSure Archive** is performed by amplifying cellassociated HIV-1 DNA from infected cells in whole-blood samples then employing NGS technology to analyze the HIV-1 polymerase region, including the full-length protease and integrase coding regions and amino acids 1-400 of reverse transcriptase.





GenoSure Archive® Sample Report

Gl	? <i>no\$</i>	ive	: HIV-1 Next Generation DNA Sequencing Assay			BIOSCIENCES			
45 O	I H. Pepkowitz, I vster Point Blvd San Francisco, C			Client: Phone:	Project: Fax:				
Patier	t Name		DOB	Patient ID/Med	lical Record # Gender	Monogram Accession #			
Date (Collected		Date Received	Date Reported	Mode	Report Status	-		
Refer	ing Physician				Reference Lab IE		-		
Comm	ents				LIV 1 Subture		-		
					HIV-1 Subtyp	3. D	-		
	Generic Name	Brand Name	Assessment	-	tance Associated Mutations De	etected Comments			
	Abacavir	Ziagen	Resistance Possible						
	Didanosine	Videx	Resistance Possible						
NRT	Emtricitabine	Emtriva	Resistant	M184M/V, K219K/E					
	Lamivudine	Epivir	Resistant	M184M/V, K219K/E	ConoCur	A #IV-1 Next			🗧 Monogram
	Stavudine	Zerit	Sensitive	T69T/N	GenoSur	Generation			DIOCOLENIOED
	Tenofovir	Viread	Sensitive	None	archiv	DNA Sequencing			S BIOSCIEINCES
	Zidovudine	Retrovir	Sensitive	None		assay 🖉			LabCorp Specialty Testing Group
NRTI	Efavirenz	Sustiva	Resistant /	L100L/I, K103K/N					
	Etravirenz	Intelence	Resistant	L100L/I, V179I/T					
	Nevirapine	Viramune	Resistant	L100L/I, K103K/N, V179	Samuel H. Pepkowitz, MD, Med		Client: Pro	ject:	
	Rilpivirine	Edurant	Resistant	L100L/I, K103K/N	345 Oyster Point Blvd South San Francisco, CA 94080		Phone: Fax:		
		Luulum			Patient Name	DOB	Patient ID/Medical Record #	Gender	Monogram Accession #
	Dolutegravir	Tivicay	Sensitive	None					
Z	Elvitegravir	Vitekta	Sensitive	None	Date Collected	Date Received	Date Reported	Mode	Report Status FINAL
	Raltegravir	Isentress	Sensitive	None					
		Deviates	Sensitive	L33L/I, E35E/D, D60E			and interpreted using an advanced prop ropriate for the following dosages: AMF		
	Atazanavir	Reyataz	Sensitive	L33L/I, E35E/D, D60E	800mg/200mg BID; LPV/r 400	BID; TPV/r 500mg/200mg BID; and DI	RV/r 600mg/100	mg BID.	
		Reyataz / r Prezista / r	Sensitive	None	* Mixtures are indicated by ami	no acids separated by a slash. Deletion	ns in the amino acid sequence are indic	ated by a " sym	IDOI.
	Darunavir		Sensitive	E35E/D	<u>0</u>	T		M 184	K 219
	Fosamprenavir	Crixivan / r	Sensitive	L33L/I	VLU VLU	T		184 M V	219 K E
	Indinavir	Kaletra	Sensitive	None					
	Lopinavir	Viracept	Sensitive	L33L/I, E35E/D	100 5	103 179 K I			
		Norvir	Sensitive	L33L/I, E35E/D	* 1	N T			
	Ritonavir	Invirase / r	Sensitive	E35E/D		L E 33 35	D 60		
	Saquinavir Tipranavir	Aptivus / r	Sensitive	L33L/I, E35E/D	5	L E I D	E		
		·			K275R, R277K, Q278H, T28	DL/I, Q102K, K103K/N, K122P, C162D, E16 86T/A, V293I, E297E/K, S322T, G335C, M3 T125A, G163E/Q, V201I, V234L	89K, F171Y, D177E, I178M, V179//T, M184 357T, K358R, A360T, A3761, T377K, T386	M/V, G196G/E, T2 I, A400T	200T/A, R211K, K219K/E, V245E, A272P,
					Genotype Comments (clini				
					1 Assessment for this drug wa	cal significance may vary) as derived considering the sensitizing effect as derived considering the sensitizing effect			

For more information on interpreting this report, please visit www.MonogramBio.com or call Customer Service at 800-777-0177 between the hours of 6:30am to 6:00pm PT Monday through Friday. Conduct Anthew is a DNA sequencing assy that usis exclamation to analyze the protase (amino acids 1-90), reverse transcriptae (amino acids 1-00) and integrase (amino acids 1-280), coding regions derived from HV-1 cell associated DNA. Subtype is determined using the protase and reverse transcriptae seguence information. This assy meets the standards for performance characterist and all other quality control and assume requirements established by the Cincil all boortour provement Annothemets. The results should not be used at the sociatific for performance characterist results have been disclosed by our from confidential records protected by law and are not to be disclosed to unauthorized persons. Further disclosure of these results is prohibited without specific consent of the presents whom the persons, or some method by law. User in trues?. eneration sequencing to analyze the protease (amino acids 1-99), reverse transcriptase (amino acids 1-400) and integrase (amino acids 1-288) be is determined using the protease and reverse transcriptase sequence information. This assay meets the standards for performance characteristic listed by the Cinical laboratory improvement Amendments. The results should not be used as the sec circuits for patient management. The rotected by law and are not to be disclosed to unauthorized persons. Further disclosure of these results is prohibited without specific consent of the

Page 2 of 2

References

1. Günthard H, Aberg JA, Eron JJ, et al. Antiretroviral Treatment of Adult HIV Infection 2014 Recommendations of the International Antiviral Society–USA Panel. JAMA. 2014;312(4):410-425. 2. White KL, Toma J, Napolitano LA, et.al. Genotypic Analyses of Pre-Existing HIV-1 Drug Resistance in Proviral HIV-1 DNA from PBMCs in Suppressed Patients Switching to RPV/FTC/TDF. 2013; International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. Poster 67.

Site O7.
Simmonds P, Zhang LQ, McOmish F, et al. Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis. *J Virol.* 1991; 65(11):6266-76.

4. Vandamme A-M, Camacho RJ, Ceccherini-Silberstein F, et al. European Recommendations for the Clinical Use of HIV Drug Resistance Testing: 2011 Update. AIDS Rev. 2011; 13:77-108.





Test Name	GenoSure Archive®	GenoSure Archive® Plus Trofile® DNA		
Test Number	551776	552020		
Specimen Collection	4 mL lavender-top (EDTA) whole blood, frozen	8 mL lavender-top (EDTA) whole blood, frozen		
Limitation	This procedure should be used for patients with documented HIV-1 infection and undetectable viral load or low level viremia.	This procedure should be used for patients with documented HIV-1 infection and undetectable viral load or low level viremia.		